The Biological Command Node
Clinical
Capital.
Vienna is home to 646 life-science companies employing 49,000 people; the Vienna BioCenter alone hosts 2,800 people from more than 80 countries. We structure clinical development, eligibility and regulatory evidence — and separate what funds a trial from what carries the location.
Engage Biotech →Biomedical
Advantage.
Engineering fiscal efficiency for clinical development.
646 companies, 49,000 employees
Vienna is Austria's densest life-science location: 646 companies, 49,000 employees and around €22.7 billion in annual revenue. The Vienna BioCenter combines six research institutes and 42 companies on 130,000 m². Across Austria, 1,174 companies employ 73,400 people.
EU Biotech Act and HTA
The EU Biotech Act is a draft regulation in procedure (2025/0406(COD)) intended to speed up authorisation and biomanufacturing in Europe. The EU HTA Regulation has applied to new active substances since 12 January 2025. Both change the evidence required at the point of authorisation. Building the trial architecture around them avoids duplicated work.
14 % research premium — including clinical research
The research premium is 14 % of eligible R&D expenditure and is paid through the tax account (Abgabenkonto). In-house research is uncapped; the €1 million limit applies only to contract research (maximum premium €140,000). Pre-clinical and clinical trials qualify as long as the boundary to routine care is documented. The FFG Basisprogramm funds project volume beyond that; double funding of the same costs is excluded.
The clock. The Biotech Act.
Europe wants biotech development and manufacturing back. The Biotech Act sets the frame; national funding is the lever. A location advantage is only sustainable if it survives the next funding period: a recurring research premium, a grown cluster and proximity to authorisation.
14,000 m² at Life Science Center Vienna, around €170 million invested, AITHYRA as first tenant from 2029.